Remove Bioavailability Remove Contract Manufacturing Remove Research
article thumbnail

XPhyto Announces Drug Formulation Strategy and 2021 Milestones Innovation to Impact

The Pharma Data

. “The addition of scalable in-house manufacturing capability creates the potential for significant growth across virtually all of our development and commercialization programs.” ” Vektor is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany.

Drugs 52
article thumbnail

Nanoparticles: Emerging Stars for Pharmaceutical Industry

Roots Analysis

In fact, it has been observed that around 40% of the pharmaceutical products approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the prime reasons that leads to failure in obtaining approval authorization. Nanoparticles Contract Manufacturing.

article thumbnail

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. The Evolving Landscape of Biopharmaceutical Excipient Manufacturing Domain.